Polycystic Ovary Syndrome (PCOS) is a common cause of infertility,
requiring antioestrogen and, possibly, gonadotropin treatment for the induction
of ovulation. However, patients suffering
from this disease need long-term treatment since PCOS is associated with
an increased risk of metabolic syndrome, hyperinsulinemia, oxidative stress,
inflammation, cardiovascular disease, and cancer. Allopathic treatment includes
the continuous use of oral contraceptives, preferentially with complementary
anti-androgen activity, and metformin. However, these treatments only partially
correct all aspects of the disease, while carrying potential adverse effects per
se. Complementary and alternative medicine (CAM) offers opportunities for
treatment through the use of nutraceuticals containing plant extracts,
minerals, and vitamins with antioxidant, anti-inflammatory, and adaptogen
capacity, as well as for correcting insulin resistance. Here we justify the
formulation of the nutraceutical QALY® (Jona Pharma, Elversele, Belgium) that
is composed of Ubiquinone Q10, the vitamins B9 and B12, the salts of zinc and
selenium, the biomass of Haematococcus
pluvialis, and the extracts of Mediterranean pine bark and of Rhodiola rosea. This can be complemented
by phytotherapy with the extract of Momordica
charantia plus alfa lipoic acid (Momordica plus®).
References
[1]
Comhaire, F. (2015) Treating Hyperinsulinemia with Momordica Charantia. Journal of Metabolic Syndrome, 4, 3.
[2]
Comhaire, F. (2010) The Role of Food Supplementation in the Treatment of the Infertile Couple and for Assisted Reproduction. Andrologia, 42, 331-340.
https://doi.org/10.1111/j.1439-0272.2009.01025.x
[3]
Decleer, W., Comhaire, F., De Clerck, K., et al. (2020) Preconception Nutraceutical Food Supplementation Can Prevent Oxidative and Epigenetic DNA Alterations Induced by Ovarian Stimulation for IVF and Increases Pregnancy Rates. Facts, Views & Vision in ObGyn, 7, 23-30.
[4]
Comhaire, F. and Deslypere, J.P. (2020) News and Views in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): The Role of Co-Morbidity and Novel Treatments. Medical Hypotheses, 134, Article ID: 109444.
https://doi.org/10.1016/j.mehy.2019.109444
[5]
Comhaire, F. and Decleer, W. (2020) Can the Biological Mechanisms of Ageing Be Corrected by Food Supplementation. The Concept of Health Care over Sick Care. The Aging Male, 23, 1146-1157. https://doi.org/10.1080/13685538.2020.1713080
[6]
Comhaire, F. (2020) Novel Perspectives for Treating and Preventing Dementia by Complementary Medicine. International Journal of Clinical Studies & Medical Cases, 4, 1-6. https://doi.org/10.46998/IJCMCR.2020.04.000083
[7]
Zuo, T., Zhu, M. and Xu, W. (2016) Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxidative Medicine and Cellular Longevity, 2016, Article ID: 8589318. https://doi.org/10.1155/2016/8589318
[8]
Mohammadi, M. (2019) Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review. International Journal of Preventive Medicine, 10, 86.
https://doi.org/10.4103/ijpvm.IJPVM_576_17
[9]
Amini, L., Tehranian, N., Movahedin, M., et al. (2015) Antioxidants and Management of Polycystic Ovary Syndrome in Iran: A Systematic Review of Clinical Trials. Iranian Journal of Reproductive Medicine, 13, 1-8.
[10]
Ekpe, L., Inaku, K. and Ekpe, V. (2018) Antioxidant Effects of Astaxanthin in Various Diseases—A Review. Journal of Molecular Pathophysiology, 7, 1-6.
https://doi.org/10.5455/jmp.20180627120817
[11]
Dabravolski, S., Nikiforov, N., Eid, A.H., et al. (2021) Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 22, 3923. https://doi.org/10.3390/ijms22083923
[12]
Izadi, A., Ebrahimi, S., Shirazi, S., et al. (2019) Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 104, 319-327.
https://doi.org/10.1210/jc.2018-01221
[13]
D’Andrea, G. (2010) Pycnogenol: A Blend of Procyanidins with Multifaceted Therapeutic Applications? Fitoterapia, 81,724-736.
https://doi.org/10.1016/j.fitote.2010.06.011
[14]
Shorakae, S., Ranasinha, S., Abell, S., et al. (2018) Inter-Related Effects of Insulin Resistance, Hyperandrogenism, Sympathetic Dysfunction and Chronic Inflammation in PCOS. Clinical Endocrinology, 89, 628-633.
https://doi.org/10.1111/cen.13808
[15]
Gulati, O.P. (2015) Pycnogenol® in Metabolic Syndrome and Related Disorders. Phytotherapy Research Phytotherapy Research, 29, 949-968.
https://doi.org/10.1002/ptr.5341
[16]
Belcaro, G., Luzzi, C.R., Cesarone, M.R., et al. (2013) Pycnogenol® Supplementation Improves Health Risk Factors in Subjects with Metabolic Syndrome. Phytotherapy Research, 10, 1572-1578. https://doi.org/10.1002/ptr.4883
[17]
Golbidi, S., Badran, M. and Laher, I. (2011) Diabetes and Alpha Lipoic Acid. Frontiers in Pharmacology, 2, 69. https://doi.org/10.3389/fphar.2011.00069
[18]
Goodarzi, M.O., Carmina, E. and Azziz, R. (2015) DHEA, DHEAS and PCOS. The Journal of Steroid Biochemistry and Molecular Biology, 145, 213-225.
https://doi.org/10.1016/j.jsbmb.2014.06.003
[19]
Panossian, A., Hambardzumyan, M., Hovhanissyan, A., et al. (2007) The Adaptogens Rhodiola and Schizandra Modify the Response to Immobilization Stress in Rabbits by Suppressing the Increase of Phosphorylated Stress-Activated Protein Kinase, Nitric Oxide and Cortisol. Drug Target Insights, 2, 39-54.
https://doi.org/10.1177/117739280700200011
[20]
Loverro, G., Lorusso, F., Mei, L., at al. (2002) The Plasma Homocysteine Levels Are Increased in Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation, 53, 157-162. https://doi.org/10.1159/000058367
[21]
Kilicdag, E.B., Bagis, T., Tarim, E., et al. (2005) Administration of B-Group Vitamins Reduces Circulating Homocysteine in Polycystic Ovarian Syndrome Patients Treated with Metformin: A Randomized Trial. Human Reproduction, 20, 1521-1528.
https://doi.org/10.1093/humrep/deh825
[22]
Kazerooni, T., Asadi, N., Dehbashi, S., et al. (2008) Effect of Folic Acid in Women with and without Insulin Resistance Who Have Hyperhomocysteinemic Polycystic Ovary Syndrome. International Journal of Gynecology & Obstetrics, 101, 156-160.
https://doi.org/10.1016/j.ijgo.2007.10.024
[23]
Yang, H.Y., Lee, H.S., Huang, W.T., et al. (2018) Increased Risk of Fractures in Patients with Polycystic Ovary Syndrome: A Nationwide Population-Based Retrospective Cohort Study. Journal of Bone and Mineral Metabolism, 36, 741-748.
https://doi.org/10.1007/s00774-017-0894-8
[24]
Doroshow, J.H. and Juhasz, A. (2019) Modulation of Selenium-Dependent Glutathione Peroxidase Activity Enhances Doxorubicin-Induced Apoptosis, Tumour Cell Killing and Hydroxyl Radical Production in Human NCI/ADR-RES Cancer Cells Despite High-Level P-Glycoprotein Expression. Free Radical Research, 53, 882-891.
https://doi.org/10.1080/10715762.2019.1641602
[25]
Yin, W., Falconer, H., Yin, L., et al. (2019) Association between Polycystic Ovary Syndrome and Cancer Risk. JAMA Oncology, 5, 106-1017.
https://doi.org/10.1001/jamaoncol.2018.5188
[26]
Coskun, A., Arikan, T., Kilinc, M., et al. (2013) Plasma Selenium Levels in Turkish Women with Polycystic Ovary Syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 168, 183-186.
https://doi.org/10.1016/j.ejogrb.2013.01.021
[27]
Jamilian, M., Razavi, M., Kashan, Z., et al. (2015) Metabolic Response to Selenium Supplementation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Endocrinology, 82, 885-891.
https://doi.org/10.1111/cen.12699
[28]
Zhang, J., Bao, Y., Zhou, X., et al. (2019) Polycystic Ovary Syndrome and Mitochondrial Dysfunction. Reproductive Biology and Endocrinology, 17, Article No. 67. https://doi.org/10.1186/s12958-019-0509-4
[29]
Guler, I., Himmetoglu, O., Turp, A., et al. (2014) Zinc and Homocysteine Levels in Polycystic Ovary Syndrome Patients with Insulin Resistance. Biological Trace Element Research, 158, 297-304. https://doi.org/10.1007/s12011-014-9941-7
[30]
Salek, M., Clark, C.C.T., Taghizadeh, M., et al. (2019) N-3 Fatty Acids as Preventive and Therapeutic Agents in Attenuating PCOS Complications. EXCLI Journal, 18, 228-575.
[31]
Mao, T., Li, T., Zhao, H., et al. (2021) Identification of Epigenetic Interaction between microRNA and DNA Methylation Associates with Polycystic Ovarian Syndrome. Journal of Human Genetics, 66, 123-137.
https://doi.org/10.1038/s10038-020-0819-6
[32]
Baylin, S.B. and Herman, J.G. (2000) DNA Hypermethylation in Tumorigenesis: Epigenetics Joins Genetics. Trends in Genetics, 16, 168-174.
https://doi.org/10.1016/S0168-9525(99)01971-X
[33]
Campbell, D.J.T., Campbell, D.B., Ogundeji, Y., et al. (2021) First-Line Pharmacotherapy for Incident Type 2 Diabetes: Prescription Patterns, Adherence and Associated Costs. Diabetic Medicine, 38, e14622. https://doi.org/10.1111/dme.14622
[34]
Martin, D., Thaker, J., Shreve, M., et al. (2021) Assessment of Vitamin B12 Deficiency and B Screening Trends for Patients on Metformin: A Retrospective Cohort Case Review. BMJ Nutrition, Prevention & Health, 4, 30-35.
https://doi.org/10.1136/bmjnph-2020-000193
[35]
Bannigida, D.M., Nayak, B.S. and Vijayraghavan, R. (2020) Insulin Resistance and Oxidative Marker in Women with PCOS. Archives of Physiology and Biochemistry, 126, 183-186. https://doi.org/10.1080/13813455.2018.1499120
[36]
Jones, A.G. and Hatterslay, A.T. (2013) The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes. Diabetic Medicine, 30, 103-117.
https://doi.org/10.1111/dme.12159
[37]
Gunalan, E., Yaba, A. and Yilmaz, B. (2018) The Effect of Nutrient Supplementation in the Management of Polycystic Ovary Syndrome-Associated Metabolic Dysfunctions: A Critical Review. Journal of the Turkish-German Gynecological Association, 19, 220-232. https://doi.org/10.4274/jtgga.2018.0077
